Physician profile
Lisha Thomas
NPI 1174117105
$2,961.96
in general payments reported to CMS, 2019-2025
30 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $956 · 2023: $435 · 2024: $266 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $485.69 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $355.86 | 2021-2024 | Airsupra, Farxiga |
| Abbvie INC. | $277.37 | 2021-2023 | |
| Novo Nordisk INC | $244.87 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $201.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.64 | 2021-2024 | |
| Mannkind Corporation | $118.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.33 | 2021-2023 | Jardiance |
| Inspire Medical Systems, INC. | $113.18 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $111.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $88.25 | 2022-2025 | |
| Amgen INC. | $70.46 | 2021-2024 | Otezla, Repatha |
| Mylan Specialty L.P. | $65.28 | 2022 | |
| Glaxosmithkline, LLC. | $60.92 | 2022-2023 | Arexvy |
| Janssen Pharmaceuticals, INC | $41.43 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.41 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.39 | 2022 | |
| Sun Pharmaceutical Industries INC. | $37.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $37.08 | 2021-2022 | |
| Boston Scientific Corporation | $35.39 | 2023 | Watchman Access System |
| Apellis Pharmaceuticals, INC. | $29.13 | 2025 | Empaveli |
| Biohaven Pharmaceutical Holding Company LTD. | $27.59 | 2022 | |
| Ethicon US, LLC | $27.08 | 2021 | |
| Pfizer INC. | $26.60 | 2025 | |
| Genentech USA, INC. | $22.72 | 2025 | Gazyva |
| E.R. Squibb & Sons, L.L.C. | $19.97 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.64 | 2021 | |
| Cmp Pharma, INC. | $16.92 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.03 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.